Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer

AI Insight

This article from the New England Journal of Medicine discusses the use of enfortumab vedotin (an antibody-drug conjugate targeting Nectin-4) combined with pembrolizumab (an immune checkpoint inhibitor) in the perioperative setting for bladder cancer patients. The combination therapy aims to improve outcomes by treating cancer both before and after surgical intervention, potentially reducing recurrence rates and improving overall survival in muscle-invasive bladder cancer.

Why it matters

Perioperative treatment strategies combining targeted therapy with immunotherapy represent an evolving approach to bladder cancer management that could significantly improve patient outcomes compared to surgery alone or traditional chemotherapy. This combination may offer a more effective treatment option for patients with muscle-invasive bladder cancer who are candidates for surgical resection.